Hansen Medical's Magellan(TM) Robotic System Utilized in Two

Hansen Medical's Magellan(TM) Robotic System Utilized in Two
Successful Live Cases at the 25th Annual International Symposium on
Endovascular Therapy 
MOUNTAIN VIEW, CA -- (Marketwire) -- 01/23/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that its Magellan(TM) Robotic System was utilized in two
successful live endovascular aortic aneurysm repair (EVAR) cases
broadcast at the 25th Annual International Symposium on Endovascular
Therapy (ISET), on January 22nd at the Fontainebleau Miami Beach
Hotel in Miami, FL. Both live cases were performed by Dr. Barry
Katzen, founder and Medical Director of the Baptist Cardiac &
Vascular Institute (Baptist Hospital of Miami), and a course director
at ISET.  
"We are very pleased to have our Magellan System featured in two live
cases at this prominent meeting for interventional radiologists,
cardiologists and endovascular surgeons," said Bruce Barclay,
president and CEO of Hansen Medical. "Live cases such as these, and
the two performed by Dr. Katzen as part of the TCT conference last
October, help demonstrate the real-world medical utility of our
robotic system, and how it can enhance endovascular procedures." 
"Today's cases went extremely well," said Dr. Katzen. "They showed
that robotic catheters can play a valuable role in vascular
procedures, and showed the promise of the technology for future
clinical applications."  
About the Magellan(TM) Robotic System
 Hansen Medical's Magellan
Robotic System is based upon the flexible robotic technology
incorporated in the Sensei-X(R) Robotic Catheter System currently
sold in the U.S. and Europe, which has been used in nearly 10,000
patients, but includes a number of key enhancements. In particular,
the Magellan Robotic System: 


 
--  Provides solid catheter stability for placement of therapeutic
    devices.
--  Is designed to enable predictable procedure times and increased case
    throughput.
--  Allows for independent, individual robotic control of the distal tips
    of both the outer sheath and the inner leader catheter, as well as
    robotic manipulation of standard guidewires.
--  Is designed to allow for sufficient extension inside the body to
    access hard to reach peripheral anatomy.
--  Preserves the open architecture featured in the Sensei System to allow
    for the subsequent use of many 6F therapeutic devices on the market
    today.
--  Is designed to potentially reduce physician radiation exposure and
    fatigue by employing a remote physician workstation.

  
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System, Magellan
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei(R) X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment of
cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.  
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012 filed with the SEC on
November 9, 2012 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer 
Hansen Medical, Inc. 
650.404.5800  
FTI Consulting, Inc.
Brian Ritchie
212.850.5683 
brian.ritchie@fticonsulting.com  
John Capodanno
212.850.5705
john.capodanno@fticonsulting.com 
 
 
Press spacebar to pause and continue. Press esc to stop.